Session Information

WCLC 2017

18th World Conference on Lung Cancer

Conference Program for the 18th World Conference on Lung Cancer in Yokohama, Japan

Download PDF of the Conference Program: Click Here.
Onsite Conference Program Addendum (17/10/2017): Click Here.
Download PDF of the Abstract Book: Click Here.
Financial Disclosure Summary (PDF): Click Here.
Presentation Date(s):
- Oct 15 - 18, 2017
- Total Presentations: 2295
Register to Attend WCLC Return to WCLC 2017 Website Switch to Virtual Meeting
Enter Virtual Meeting Access Code

All Days Saturday
October 14 Sat
Oct 14 Sunday
October 15 Sun
Oct 15 Monday
October 16 Mon
Oct 16 Tuesday
October 17 Tue
Oct 17 Wednesday
October 18 Wed
Oct 18

Filter Results:

Show Only CME Accredited Sessions

18982

+
JCSE 01 - Joint IASLC/CSCO/CAALC Session: Immunotherapy for Management of Lung Cancer: Ongoing Research from East and West
- 07:30 - 11:30
- 10/15/2017
- Location: F203 (Annex Hall)
- Type: Joint Session IASLC/CSCO/CAALC
- Track: Immunology and Immunotherapy
- Moderators:C. Bai, Fred R. Hirsch, Tony SK Mok, Yi-Long Wu
- 22304
  
  +
  
  JCSE 01.12 - A Phase II Study of Fruquintinib in Combination with Gefitinib in Stage IIIb/IV NSCLC Patients Harboring EGFR Activating Mutations
  
  10:35 - 10:50 | Presenter: Shun Lu | Author(s): J. Zhou, X. Niu, M. Chen, Y. Hua, W. Su
  Abstract
  
  Loading...
20152

+
P1.03 - Chemotherapy/Targeted Therapy
- 09:30 - 16:00
- 10/16/2017
- Location: Exhibit Hall (Hall B + C)
- Type: Poster Session with Presenters Present
- Track: Chemotherapy/Targeted Therapy
- 22562
  
  +
  
  P1.03-007 - A Real-World Study of Clinicopathological Characteristics and Survival Outcome in Advanced ALK-Positive Non-Small-Cell Lung Cancer
  
  09:30 - 09:30 | Presenter: Xiao Hu | Author(s): Y. Jin, M. Chen, Y. Chen, X. Shi, X. Yu
  Abstract
  
  Loading...
20114

+
MA 01 - SCLC: Research Perspectives
- 11:00 - 12:30
- 10/16/2017
- Location: Room 503
- Type: Mini Oral
- Track: SCLC/Neuroendocrine Tumors
- Moderators:John V Heymach, Eun Kyung Cho
- 22874
  
  +
  
  MA 01.11 - Timing of Thoracic Radiotherapy Is More Important Than Dose Escalation in Patients with Limited-Stage Small Cell Lung Cancer
  
  12:10 - 12:15 | Presenter: Xiao Hu | Author(s): B. Xia, Y. Bao, Y.J. Xu, J. Wang, H.L. Ma, Y. Jin, M. Fang, H.R. Tang, M.Y. Chen, B.Q. Dong, X. Fu, M. Chen
  Abstract
  
  Loading...
18972

+
P2.02 - Biology/Pathology
- 09:30 - 16:00
- 10/17/2017
- Location: Exhibit Hall (Hall B + C)
- Type: Poster Session with Presenters Present
- Track: Biology/Pathology
- 23201
  
  +
  
  P2.02-003 - A Practical Prognostic lncRNA Signature for Lung Squamous Cell Carcinoma
  
  09:30 - 09:30 | Presenter: Xiaoshun Shi | Author(s): X. Le, X. Li, K. Huang, B. Liu, V.Y. Luo, Y. Liu, Z. Wu, A.M. Chen, Y. Liang, J. Zhang
  Abstract
  
  Loading...
18975

+
P3.01 - Advanced NSCLC
- 09:30 - 16:00
- 10/18/2017
- Location: Exhibit Hall (Hall B + C)
- Type: Poster Session with Presenters Present
- Track: Advanced NSCLC
- 23886
  
  +
  
  P3.01-027 - TET2 Mutation as a Novel Mechanism of Acquired Resistance to EGFR TKIs Identified by a Mutational Profiling Using NGS
  
  09:30 - 09:30 | Presenter: Xiao Hu | Author(s): Y. Jin, M. Chen, X. Yu
  Abstract
  
  Loading...
- 23929
  
  +
  
  P3.01-070 - A Phase II Study of Fruquintinib in Combination with Gefitinib in Stage IIIb/IV NSCLC Patients Harboring EGFR Activating Mutations
  
  09:30 - 09:30 | Presenter: Shun Lu | Author(s): J. Zhou, X. Niu, M. Chen, Y. Hua, W. Su
  Abstract
  
  Loading...
20193

+
P3.14 - Radiotherapy
- 09:30 - 16:00
- 10/18/2017
- Location: Exhibit Hall (Hall B + C)
- Type: Poster Session with Presenters Present
- Track: Radiotherapy
- 24194
  
  +
  
  P3.14-004 - Pathological Study on the Clinical Target Volume (CTV) in Limited-Stage SCLC for CT-Simulation Based Thoracic Radiotherapy Planning
  
  09:30 - 09:30 | Presenter: Xiao Hu | Author(s): H. Zhu, J. Liu, C. Yu, L. Zhu, Y. Tong, W. Sun, W. Mao, M. Chen
  Abstract
  
  Loading...

Session Information

WCLC 2017

18th World Conference on Lung Cancer

Enter Virtual Meeting Access Code

+

JCSE 01 - Joint IASLC/CSCO/CAALC Session: Immunotherapy for Management of Lung Cancer: Ongoing Research from East and West

+

JCSE 01.12 - A Phase II Study of Fruquintinib in Combination with Gefitinib in Stage IIIb/IV NSCLC Patients Harboring EGFR Activating Mutations

+

P1.03 - Chemotherapy/Targeted Therapy

+

P1.03-007 - A Real-World Study of Clinicopathological Characteristics and Survival Outcome in Advanced ALK-Positive Non-Small-Cell Lung Cancer

+

MA 01 - SCLC: Research Perspectives

+

MA 01.11 - Timing of Thoracic Radiotherapy Is More Important Than Dose Escalation in Patients with Limited-Stage Small Cell Lung Cancer

+

P2.02 - Biology/Pathology

+

P2.02-003 - A Practical Prognostic lncRNA Signature for Lung Squamous Cell Carcinoma

+

P3.01 - Advanced NSCLC

+

P3.01-027 - TET2 Mutation as a Novel Mechanism of Acquired Resistance to EGFR TKIs Identified by a Mutational Profiling Using NGS

+

P3.01-070 - A Phase II Study of Fruquintinib in Combination with Gefitinib in Stage IIIb/IV NSCLC Patients Harboring EGFR Activating Mutations

+

P3.14 - Radiotherapy

+

P3.14-004 - Pathological Study on the Clinical Target Volume (CTV) in Limited-Stage SCLC for CT-Simulation Based Thoracic Radiotherapy Planning

Stay Connected